Mathematics · Mathematical Physics
Characterization of Alpha-Toxin hla Gene Variants, Alpha-Toxin Expression Levels, and Levels of Antibody to Alpha-Toxin in Hemodialysis and Postsurgical Patients with Staphylococcus aureus
Vance G. Fowler, C Mark T. Esserb
See on the mapAbstract
Alpha-toxin is a major Staphylococcus aureus virulence factor. This study evaluated potential relationships between in vitro al-pha-toxin expression of S. aureus bloodstream isolates, anti-alpha-toxin antibody in serum of patients with S. aureus bactere-mia (SAB), and clinical outcomes in 100 hemodialysis and 100 postsurgical SAB patients. Isolates underwent spa typing and hla sequencing. Serum anti-alpha-toxin IgG and neutralizing antibody levels were measured by using an enzyme-linked immu-nosorbent assay and a red blood cell (RBC)-based hemolysis neutralization assay. Neutralization of alpha-toxin by an anti-al-pha-toxin monoclonal antibody (MAbMEDI4893) was tested in an RBC-based lysis assay. Most isolates encoded hla (197/200; 98.5%) and expressed alpha-toxin (173/200; 86.5%). In vitro alpha-toxin levels were inversely associated with survival (cure, 2.19 g/ml, versus failure, 1.09g/ml; P< 0.01). Both neutralizing (hemodialysis, 1.26 IU/ml, versus postsurgical, 0.95; P< 0.05) and IgG (hemodialysis, 1.94 IU/ml, versus postsurgical, 1.27; P< 0.05) antibody levels were higher in the hemodialysis popula-tion. Antibody levels were also significantly higher in patients infected with alpha-toxin-expressing S. aureus isolates (P< 0.05). Levels of both neutralizing antibodies and IgG were similar among patients who were cured and those not cured (failures). Se-quence analysis of hla revealed 12 distinct hla genotypes, and all genotypic variants were susceptible to a neutralizing monoclo-nal antibody in clinical development (MEDI4893). These data demonstrate that alpha-toxin is highly conserved in clinical S. au-reus isolates. Higher in vitro alpha-toxin levels were associated with a positive clinical outcome. Although patients infected with